BIOC News Alert Biocept Inc (BIOC) 2.82 12/17/2014 01:59:32

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biocept Inc (BIOC) 2.82 $BIOC

Biocept Expands Worldwide Microchannel Patent Protection to South Korea
GlobeNewswire - Mon Dec 15, 8:05AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that it has been granted a patent in South Korea for its fluidic microfluidic channel. The patent, Detection or Isolation of Target Molecules Using a Microchannel Apparatus, is the subject of Korean Patent Application No. 10-2009-7003339.
BIOC: 2.82 (+0.04)

Biocept Appoints Experienced Physician as Medical Director
GlobeNewswire - Wed Dec 03, 8:24AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Veena Singh, MD, FCAP, FCAMG has joined the Company as Senior Vice President and Senior Medical Director.
BIOC: 2.82 (+0.04)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 11:45AM CST

FRO: 2.29 (-0.58), SCOK: 2.85 (+0.02), NES: 5.66 (-0.02), OIIM: 2.19 (-0.01), BDR: 2.36 (+0.02), FRED: 15.74 (-0.21), MDGN: 5.33 (+0.13), NKA: 2.99 (+0.11), BIOC: 2.82 (+0.04), RVLT: 1.25 (+0.04), DY: 30.80 (-0.16), NDRM: 6.34 (-0.47), CRNT: 1.03 (-0.10), QIHU: 55.52 (-4.13), NFEC: 1.53 (-0.05), RLI: 44.59 (+0.01), ACI: 1.70 (+0.08), APT: 2.52 (-0.07), LAKE: 9.19 (-0.46), CASY: 84.45 (-1.54)

Nasdaq stocks posting largest volume increases
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
RESN: 8.59 (-0.31), FCVA: 4.30 (-0.01), GLBZ: 12.00 (-0.32), VGGL: 3.43 (+0.28), RDI: 12.89 (+0.39), CRDC: 0.63 (+0.02), BIOC: 2.82 (+0.04), WFD: 7.20 (+0.05), PLMT: 16.06 (+0.26), JAXB: 11.25 (-0.99), SUSQ: 12.89 (-0.09), RDIB: 12.88 (+0.52)

Biocept reports Q3 loss
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:55PM CST

BIOC: 2.82 (+0.04)

Biocept Reports Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 13, 3:09PM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced its financial results for the third quarter ended September 30, 2014.
BIOC: 2.82 (+0.04)

Biocept Launches Lung Cancer Offering
GlobeNewswire - Wed Nov 12, 7:54AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor DNA and Circulating Tumor Cells (CTCs), today announced the launch of its lung cancer liquid biopsy testing that will be performed at the Company's CLIA-certified and CAP-accredited laboratory.
BIOC: 2.82 (+0.04)

Biocept reports November 13
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 10:13AM CST

BIOC: 2.82 (+0.04)

Biocept, Inc. Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:42AM CST
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), today announced that the Company will issue its financial results for the third quarter of 2014 on Thursday, November 13, 2014, after the close of the market, and will hold a conference call on this day at 4:30 p.m. ET to discuss the financial results and provide a company update.
BIOC: 2.82 (+0.04)

Biocept and Rosetta Genomics Collaborate to Evaluate microRNAs From Circulating Tumor Cells
GlobeNewswire - Mon Oct 13, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA (cfDNA) and circulating tumor cells (CTCs), and Rosetta Genomics, Ltd. (Nasdaq:ROSG), a leading molecular diagnostics company advancing microRNA-based diagnostics based on its proprietary microRNA platform technologies, today announced a collaboration that will combine both companies' platform technologies in an innovative approach to cancer diagnostics. The collaboration will utilize Biocept's patented microfluidic channel technology to capture CTCs and then apply Rosetta Genomics' technical expertise and proprietary methods to extract and analyze microRNA from these cells. The companies will test for markers currently offered by Rosetta as well as pursue new potential markers.
ROSG: 2.28 (-0.04), BIOC: 2.82 (+0.04)

Market Maker Surveillance Report. ISSC, CBK, ANV, BIOC, OMAG, TCS, Losing Stocks With Lowest Price Friction For Tuesday, October 7th 2014
M2 - Wed Oct 08, 4:24AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4746 companies with "abnormal" market making, 1204 companies with positive Friction Factors and 3932 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Tuesday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Innovative Solutions and Support Inc (NASDAQ:ISSC), Christopher & Banks Corp (NYSE:CBK), Allied Nevada Gold Corp (NYSE:ANV), BioClinica Inc (NASDAQ:BIOC), Omagine Inc (OTC:OMAG), (NYSE:TCS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
ANV: 0.85 (+0.07), CBK: 4.96 (+0.34), ISSC: 2.89 (+0.10), TCS: 18.64 (+0.49), BIOC: 2.82 (+0.04)

Biocept Expands Collaboration With MD Anderson Cancer Center
GlobeNewswire - Tue Oct 07, 7:39AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis of cell-free circulating tumor DNA and circulating tumor cells (CTCs), today announced the furthering of its collaboration with The University of Texas MD Anderson Cancer Center regarding studies focused on patients diagnosed with ovarian cancer.
BIOC: 2.82 (+0.04)

Biocept to Present at the 13th Annual BIO Investor Forum
GlobeNewswire - Tue Sep 30, 7:31AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in biomarker analysis in circulating tumor cell (CTC) and circulating tumor DNA (ctDNA), today announced that Michael Nall, Biocept President and CEO, is scheduled to present a corporate overview at the 13 Annual BIO Investor Forum on October 7, 2014 at The Palace Hotel in San Francisco.
BIOC: 2.82 (+0.04)

Biocept Granted Patent in China for Its Microfluidic Channel Technology Used to Capture Circulating Tumor Cells
GlobeNewswire - Thu Sep 18, 9:34AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that the Company has been granted a patent in China for its microfluidic channel technology used to capture CTCs. The granted patent is the subject of Chinese Patent No. ZL200780032530.2, entitled, "Detection or Isolation of Target Molecules Using a Microchannel Apparatus."
BIOC: 2.82 (+0.04)

Biocept to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Sep 04, 7:36AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that Michael Nall, Biocept President and CEO, will be presenting a corporate overview at the following upcoming investor conferences:
BIOC: 2.82 (+0.04)

Biocept Strengthens Its Circulating Tumor Cell IP Position in Europe
GlobeNewswire - Wed Sep 03, 7:30AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that the opposition period has expired for challenging the validity of its European Patent No. 1838442, entitled, "Cell Separation Using Microchannel Having Patterned Posts." This patent supports the proprietary microfluidics blood-based technology Biocept uses to capture CTCs.
BIOC: 2.82 (+0.04)

Biocept Provides Second Quarter Operational Update
GlobeNewswire - Thu Aug 14, 7:31AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today provided a business update following the recent filing with the US Securities and Exchange Commission of its Quarterly Report on Form 10-Q for the second quarter ended June 30, 2014.
BIOC: 2.82 (+0.04)

Biocept Appoints Managed Care Expert to Lead Contract and Reimbursement Strategy
GlobeNewswire - Wed Aug 06, 7:43AM CDT
Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (ctDNA) biomarker analysis, today announced that Amy McNeal has joined the Company as Senior Director of Managed Care and Reimbursement Strategies.
DGX: 62.92 (-0.29), BIOC: 2.82 (+0.04)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Epic Blue Puts $50,000 of Marketing Work to Use Locally

Updated Category News Views 136

A $50,000 pile of donated know-how can look soft on a spreadsheet, until you remember how often a small nonprofit or early-stage outfit gets ignored because it cannot afford someone to sharpen its message. Epic Blue Marketing, a women-owned firm based in Jackson, Michigan, says it provided that amount in donated and reduced-rate marketing, communications and public...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 92

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 155

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 178

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 205

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 76

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 239

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 180

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Vivid Seats Simplifies Market Structure and Tax Obligations

Updated Category News Views 221

Vivid Seats Streamlines Corporate Structure Vivid Seats Inc. (NASDAQ: SEAT), a leading online ticket marketplace, has embarked on a transformative journey to simplify its organizational framework. In a strategic move, the company has announced its Corporate Simplification Agreement, aimed at redefining how it operates while enhancing its tax efficiency and overall...

Continue Reading
NLS Pharmaceuticals Soars After Major Merger Announcement

Updated Category News Views 330

NLS Pharmaceuticals Sees Positive Stock Movement NLS Pharmaceuticals Ltd. (NASDAQ: NLSP) is experiencing significant upward momentum in its stock prices following a crucial announcement regarding a proposed merger. The company has filed a Form F-4 registration statement with the Securities and Exchange Commission, signaling an essential step toward completing this merger....

Continue Reading
Orchestra BioMed Achieves Key Financial and Operational Progress

Updated Category News Views 84

Orchestra BioMed Reports on Financial Performance and Business Updates Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO), a pioneering biomedical innovation company, recently presented its robust financial results for Q3 2024, reflecting both significant fiscal health and promising advancements in medical technology. The company is focused on elevating patient care through...

Continue Reading
Nutex Health Inc. Investors Urged to Join Securities Class Action

Updated Category News Views 130

Investors of Nutex Health Inc. Face Opportunities Amid Allegations Investors holding shares in Nutex Health Inc. are currently presented with a remarkable opportunity in light of claims surrounding securities fraud involving the Company. Founded as a notable player in the healthcare sector, Nutex Health has recently come under scrutiny due to alleged misleading statements...

Continue Reading
Empowering Resilience in Education: Embracing Failure with LetMeFail

Updated Category News Views 182

Transforming Education: LetMeFail's Innovative Approach LetMeFail is an exciting new educational initiative aimed at transforming how students perceive and deal with failure. In today's culture, where perfection is often idolized, this program makes it clear that setbacks can serve as important stepping stones toward personal growth and resilience. Unpacking the Goals of...

Continue Reading